Influenza Diagnostics Market
Global Market Study on Influenza Diagnostics: Increasing Availability of Rapid Influenza Diagnostic Tests Aiding Market Growth
Influenza Diagnostics Market is segmented by Molecular Diagnostic Tests, Traditional Diagnostic Tests, Type of Flu, end-user
The U.S. Centers for Disease Control (CDC) tracked 7 million flu cases in the U.S. in 2019, prompting tens of thousands of hospitalizations and concerns among high risk populations.
However, the high risk population for influenza consists of pregnant women, children, elderly population, healthcare workers, and immunosuppressed patients that suffer from chronic medical conditions.
Seasonal flu is a serious disease that infects a large population and causes serious illness, resulting in large number of hospitalizations and deaths every year. This factor is increasing the demand for faster diagnosis and driving the growth of the influenza diagnostics market.
Find Out More about the Report Coverage
- Abbott Laboratories
- Endress+Hauser (Analytik Jena AG)
- Becton, Dickinson and Company
- bioMérieux Inc
- Danaher Corporation (Cepheid)
- F. Hoffmann-La Roche Ltd
- GenMark Diagnostics, Inc.
- Luminex Corporation
- Meridian Bioscience, Inc
- Quidel Corporation
- Thermo Fisher Scientific Inc.
Influenza V/S. COVID-19 - Similarities and Differences
According to the Centers for Disease Control (CDC), influenza testing across the United States is higher than normal because of the COVID-19 pandemic. A similarity in influenza and COVID-19 is that, both cause respiratory issues. Additionally, both viruses are transmitted by contact fomites and droplets. Moreover, the first stage symptoms of COVID-19 and influenza (flu) are similar, wherein, patients experience fever, cough, sore throat, fatigue and body aches.
However, an important difference between the two viruses is the speed of transmission. The COVID-19 virus has a longer incubation period as compared to influenza. Additionally, influenza has a shorter serial interval (time between successive cases) than the COVID-19 virus. Lastly, the mortality rate of COVID-19 is higher than that of influenza.
With the ongoing corona virus pandemic, the need for influenza diagnostics tests and related testing has shot up dramatically, which is eventually surging the growth of the global influenza diagnostics market.
Customize this Report
Explore Intelligence Tailored to Your Business Goals.
Commercial Availability of Improved Diagnostic Tests for Influenza Infection
Rapid molecular assays are a new kind of molecular influenza diagnostic test with specificity and high sensitivity that are major developments in influenza diagnostics over recent years. Reverse transcription polymerase chain reaction (RT-PCR) and Nucleic acid labelling detection tests have greatly improved the ability to detect respiratory viruses.
Additionally, molecular tests for influenza are mainly focused on detection of specific known pathogens by NATs. NATs have several advantages over other existing diagnostic tools. They potentially can detect low levels of all-known influenza pathogens in clinical specimens, do not depend on the viability of the target microbe, and can provide results within a clinically relevant time frame.
However, commercial rapid influenza diagnostic tests are mostly used method for influenza detection owing to its ability to detect influenza viruses within 15 minutes with low to moderate sensitivity and high specificity.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
Regional Analysis of Influenza Diagnostics Market
North America and Europe currently hold more than 60% of the global influenza diagnostics market. The high prevalence of respiratory disease such as seasonal flu are propelling the demand for influenza diagnostics test in North America.
However, East Asia and South Asia are poised for significant growth over the forecast period owing to factors such as large population base, increase burden of infectious disease, and wide use of rapid influenza diagnostic tests. Increased R&D investments and government initiatives are expected to boost the demand for influenza diagnosis in these regions.
Explore Persistence Market Research’s expertise in promulgation of the business !
An extensive analysis of the influenza diagnostics market has brought our analysts to a conclusion that, the market is growing at a significant pace. Currently, rapid influenza detection tests is the target segment for major players, hence this segment dominates the global influenza diagnostics market by test type in term of market growth. Europe and North America collectively gain more than 60% of revenue share due to high adoption of influenza diagnostics test in these region. Emerging countries such as Brazil, china, and India are expected to offer lucrative opportunities for the Proteomic market growth owing to increasing awareness and initiative by local government for research and development in disease diagnostics.
Key Segments of Influenza Diagnostics Market
PMR’s study on the influenza diagnostics market offers information divided into five important segments— test type, type of flu, end user, and region. This report offers comprehensive data and information about the important market dynamics, and growth parameters associated with these categories.
Type of Flu
Key Questions Answered in PMR’s Influenza Diagnostics Market Report
- Which regions will continue to remain the most profitable regional markets for influenza diagnostics market players?
- Which factors will induce a change in the demand for influenza diagnostics during the assessment period?
- How will changing trends impact the influenza diagnostics market?
- How can market players capture the low-hanging opportunities in the influenza diagnostics market in developed regions?
- What are the winning strategies of stakeholders in the influenza diagnostics market to upscale their position in this landscape?
- What are the restraints that investors need to be aware of and tackle while investing in the influenza diagnostics market?
- What are the developmental trends in influenza diagnostics sectors that will impact the market?
- How can businesses in the influenza diagnostics market avail the growth opportunities in developed and emerging sectors?